chevron_left Categories

Other related webinars

Are Genes Patentable in the United States? (A Re...

Friday, 26th August, 2011
Time : 02:00 PM | 11:00 AM

GLP Regulations – A Simplified Overview for Ac...

Friday, 2nd December, 2011
Time : 02:00 PM | 11:00 AM

Understanding FDA Guidance on GLP for Nonclinica...

Thursday, 22nd December, 2011
Time : 02:00 PM EST | 11:00 AM PST

FDA and EMA successful development and approvals...

Friday, 22nd June, 2012
Time : 02:00 PM EST | 11:00 AM PST

Strategic insights into European (CHMP/EMA) and ...

Monday, 3rd December, 2012
Time : 02:00 PM EST | 11:00 AM PST

FDA Approvals and Insights: Understanding US-FDA...

Friday, 1st March, 2013
Time : 02:00 PM IST | 09:30 AM CET

Effective Responses to FDA Warning Letters on Qu...

Friday, 15th August, 2014
Time : 01:00 PM | 10:00 AM

FDA’s view of Purchasing Controls, regulatory ...

Friday, 3rd October, 2014
Time : 01:00 PM EST | 10:00 AM PST

A review of the FDA’s oversight, regulatory re...

Friday, 16th January, 2015
Time : 01:00 PM EST | 10:00 AM PST

Preparing for and Managing EU Notified Bodies Au...

Thursday, 28th January, 2016
Time : 01:00 PM EDT | 10:00 AM PDT

Biopharmaceutical Method Transfer – Using a Qu...

Friday, 20th May, 2016
Time : 01:00 PM EDT | 10:00 AM PDT

Quality systems for Analytical Instrumentation a...

Friday, 24th June, 2016
Time : 01:00 PM EDT | 10:00 AM PDT

Effective Investigation of Deviations & Putting ...

Friday, 2nd September, 2016
Time : 04:00 PM IST | 11:30 AM BST

NO More Written Procedure (Standard Operating Pr...

Friday, 14th October, 2016
Time : 01:00 PM EDT | 10:00 AM PDT

Best Practices in Supplier Management: Evaluatio...

Friday, 20th January, 2017
Time : 10:00 AM EST | 04:00 PM BST

Using Quality Indicators for Successful FDA QSR ...

Friday, 10th February, 2017
Time : 04:00 PM IST | 11:30 AM BST

Effective Management Reviews for FDA and Managem...

Friday, 21st April, 2017
Time : 01:00 PM EDT | 10:00 AM PDT

FDA Internal Audits - An Important Tool for Avoi...

Friday, 30th June, 2017
Time : 04:00 PM IST | 11:30 AM BST

FDA Regulatory Rules for Supply Chain and Manufa...

Friday, 4th August, 2017
Time : 11:00 AM EDT | 08:00 AM PDT

FDA - Training Modules

Friday, 28th September, 2018
Time : Set the Time | Set the Time

FDA Quality Systems Inspection Technique (QSIT) ...

Friday, 26th October, 2018
Time : 01:00 PM EDT | 10:00 AM PST

Key Element of Quality Management System Complia...

Friday, 30th August, 2019
Time : 04:00 PM IST | 11:30 AM BST

A CAPA Primer - Elements of a CAPA Program

Friday, 28th February, 2020
Time : 01:00 PM EST | 10:00 AM PST

How To Respond To FDA 483s

Wednesday, 2nd March, 2022
Time : 01:00 PM EST | 10:00 AM PST

FDA Expectations from Supplier Management for GM...

Friday, 22nd April, 2022
Time : 01:00 PM EDT | 10:00 AM PDT

The clinical, regulatory and business challenges...

Friday, 19th August, 2022
Time : 01:00 PM EST | 10:30 AM PST

The FDA CGMP and Data Integrity in Pharmaceutica...

Friday, 7th April, 2023
Time : 01:00 PM EST | 10:30 AM PST

FDA PMA Submissions - Contents, Process, Pitfall...

Friday, 21st April, 2023
Time : 01:00 PM IST | 10:00 AM PST

Complaint Handling in Compliance with FDA and IS...

Friday, 26th May, 2023
Time : 01:00 PM EST | 10:00 AM PST

Recorded Webinar

Strategic insights into European (CHMP/EMA) and American (FDA) regulatory aspects of stability

timelapse 60 mins with 10-15 mins of Q and A

Note:

This webinar occured in the past
Along with recorded webinar, copy of presentation slides will be shared
Recorded Webinar can be played unlimited times

Speaker/Presenter

Short Abstract

In the face of risk (likelihood of an unfavorable outcome) and uncertainty (range of possible outcomes), how well do you perform at decision-making? Do you strive to make good decisions or to make the right decisions? If the right decision is the descriptive result of the knowledge of an event that has already occurred, a good decision can be defined as logically consistent, defensible, transparent, and prescriptive. In the face of risk and uncertainty, the webinar addresses why you should strive to make good decisions which may lead to favorable or unfavorable outcomes.

This presentation will cover the following areas :

  • Importance of complete characterisation of drug substance and drug product prior to conducting stability.
  • Value of stability in establishing proof of comparability.
  • Diversity of EU and US, also ICH, written guidances and interpretation.
  • Shelf-life and in-use stability.
  • Biological, Biological/Product, Biologic/Device, Medicine, Product/Device.


Apply for this webinar

Who should attend

Anyone who is involved in Biological, Biological/Product, Biologic/Device, Medicine, Product/Device.

Content Disclaimer

Contents in our website are from external websites. Links to and content from external website are provided for the convenience of users. Biopractice.com takes no responsibility for the content of such links and websites.

//